search
Back to results

Perfusion CT Imaging in Lung Cancer With SBRT

Primary Purpose

Lung Cancer

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Perfusion CT Imaging
Sponsored by
University Health Network, Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Gender: male or female
  • CT ordered for baseline and follow up in patients with lung cancer and lung metastases treated with
  • Patient will sign a consent form prior to study entry
  • Lung cancer and lung metastases are biopsy proven

Exclusion Criteria:

  • Patients who are unable to give valid informed consent
  • Patients who are unwilling or unable to undergo a CT exam, including subjects with contra-indications to CT exams or intravenous contrast material administration.

Sites / Locations

  • Patrik Rogalla

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

open label

Arm Description

Perfusion CT Imaging

Outcomes

Primary Outcome Measures

Imaging of during and after SBRT treatment for lung malignancies with a combined perfusion and routine CT to assess therapy response of lung cancer and metastases.

Secondary Outcome Measures

Full Information

First Posted
March 7, 2016
Last Updated
November 20, 2018
Sponsor
University Health Network, Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT02755454
Brief Title
Perfusion CT Imaging in Lung Cancer With SBRT
Official Title
Perfusion CT Imaging in Patients With Lung Malignancies Receiving Stereotactic Body Radiation Therapy (SBRT)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
October 2013 (Actual)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
November 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Health Network, Toronto

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this study is to determine specific perfusion patterns for radiation induced lung changes and residual/recurrent lung malignancies in patients treated with stereotactic body radiotherapy SBRT and thus improve to distinguish radiation changes from residual/recurrent lung cancers. Currently CT is often unable to make a clear differentiation between benign and malignant changes in the lung after SBRT treatment necessitating additional wait time to perform follow up CTs or biopsies. Optimal treatment may be delayed. The investigators want to apply a CT perfusion sequence in addition to the routine follow up CTs with the goal to obtain perfusion values of post treatment lung changes and lung tumours. The investigators' hypothesis is that CT perfusion values will help differentiate benign post radiation changes from residual/recurrent tumour in the lung with higher confidence and may help avoid unnecessary delays in cancer treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
open label
Arm Type
Other
Arm Description
Perfusion CT Imaging
Intervention Type
Device
Intervention Name(s)
Perfusion CT Imaging
Primary Outcome Measure Information:
Title
Imaging of during and after SBRT treatment for lung malignancies with a combined perfusion and routine CT to assess therapy response of lung cancer and metastases.
Time Frame
3-6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gender: male or female CT ordered for baseline and follow up in patients with lung cancer and lung metastases treated with Patient will sign a consent form prior to study entry Lung cancer and lung metastases are biopsy proven Exclusion Criteria: Patients who are unable to give valid informed consent Patients who are unwilling or unable to undergo a CT exam, including subjects with contra-indications to CT exams or intravenous contrast material administration.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrik Rogalla, MD
Organizational Affiliation
UHN
Official's Role
Principal Investigator
Facility Information:
Facility Name
Patrik Rogalla
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2X9
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Perfusion CT Imaging in Lung Cancer With SBRT

We'll reach out to this number within 24 hrs